GlassScriptPhysician profile
Stephen M Lindsey
NPI 1558386839
$129,530.32
in general payments reported to CMS, 2019-2025
36 companies · $4,600 in 2025
The $4,600 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $11K · 2021: $15K · 2022: $14K · 2023: $5,744 · 2024: $9,115 · 2025: $4,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,196 · Consulting Fee: $6,600 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,650 · Travel and Lodging: $1,598 · Education: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,196.31 |
| Consulting Fee | $6,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,650.00 |
| Travel and Lodging | $1,597.80 |
| Education | $414.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49,634.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $43,560.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $11,700.36 | 2019-2025 | Benlysta |
| Amgen INC. | $8,695.61 | 2019-2025 | Uplizna, Tavneos, Evenity |
| Aurinia Pharma U.S., INC. | $6,796.20 | 2021-2025 | Lupkynis |
| Abbvie INC. | $2,328.12 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,989.84 | 2021-2025 | |
| Ucb, INC. | $1,178.63 | 2021-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $672.75 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $624.91 | 2019-2025 | Tremfya, Simponi Aria |
| Sanofi-Aventis U.S. LLC | $293.98 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $291.28 | 2019-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $290.27 | 2022-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $263.68 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $237.92 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $204.57 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $145.36 | 2019-2022 | |
| Radius Health, INC. | $122.49 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $111.70 | 2019 | |
| Octapharma USA, INC. | $95.51 | 2022-2024 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $83.88 | 2022-2024 | Strensiq |
| Neurelis, INC. | $47.50 | 2025 | Valtoco |
| Ultragenyx Pharmaceutical INC. | $44.04 | 2022 | |
| Fresenius Kabi USA, LLC | $31.53 | 2024 | Idacio |
| Daiichi Sankyo INC. | $20.82 | 2023 | Injectafer |
| Shire North American Group INC | $18.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.38 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.19 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $13.86 | 2024 | Arcalyst |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lindsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.